Poseida Therapeutics Presents Preclinical Data Demonstrating …Yahoo FinanceSAN DIEGO, April 04, 2017– Poseida Therapeutics Inc., a San Diego-based company translating best-in-class gene editing technologies into lifesaving …and more »… Continue reading
|
Bellicum Pharmaceuticals Announces Late-Breaking Presentation of Dual-Switch CAR–T / TCR Technology at AACR
GlobeNewswire (press release) In a late-breaking poster presentation titled “Dual-switch HER2 CAR–T cells: Small molecule-regulated GO and STOP switches to target solid cancer in vivo,” Bellicum scientists tested the novel dual-switch platform in solid tumors by combining both the … |
|
Bellicum Pharmaceuticals Announces Late-Breaking Presentation of Dual-Switch CAR–T / TCR Technology at AACR
GlobeNewswire (press release) In a late-breaking poster presentation titled “Dual-switch HER2 CAR–T cells: Small molecule-regulated GO and STOP switches to target solid cancer in vivo,” Bellicum scientists tested the novel dual-switch platform in solid tumors by combining both the … |
|
Bellicum Pharmaceuticals Announces Late-Breaking Presentation of Dual-Switch CAR–T / TCR Technology at AACR
Nasdaq In a late-breaking poster presentation titled “Dual-switch HER2 CAR–T cells: Small molecule-regulated GO and STOP switches to target solid cancer in vivo,” Bellicum scientists tested the novel dual-switch platform in solid tumors by combining both the … |
|
Bellicum Pharma (BLCM) to Present Preclinical Data on CAR–T and TCR Product Candidates at AACR
StreetInsider.com In a late-breaking poster presentation titled “Dual-switch HER2 CAR–T cells: Small molecule-regulated GO and STOP switches to target solid cancer in vivo,” Bellicum scientists tested the novel dual-switch platform in solid tumors by combining both the … |